doi: 10.3389/fphar.2025.1618079 Received 28 April 2025 Accepted 08 July 2025 Published 24 July 2025 Volume 16 - 2025 Edited by Karuna Rasineni, University of Nebraska Medical Center, United States Reviewed by Yang Yang, Chinese PLA General Hospital, China Asher Rajkumar Rajan, University of Nebraska Medical Center, United States Updates Copyright 2025 Xie, Yang, Tian and Chen
#PMOS #PCOS #MetabolicHealth #InsulinResistance #WomensHealth #LifestyleMedicine To view or add a comment, sign in Our CEO, Claire McDonnell, on why the move from PCOS to PMOS is more than a name change
Who Is More Likely to Get Semaglutide Side Effects
The interplay between GIP and GLP-1 creates synergistic effects that neither pathway achieves alone, which is why tirzepatide results exceeded those of semaglutide in head-to-head comparisons
Starting at a lower dose (e.g., 2 mg instead of 4 mg) helps reduce gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation, which are more common with higher initial doses
Despite the above preclinical evidence, there is no significant effect on appetite, energy intake or energy expenditure following a GIP acute infusion over a short period
